| Similar Articles |
|---|
 |
Pharmaceutical Executive
September 1, 2011 |
Pharma and Social Media: Ready to Make Nice? The time is right for industry to overcome its social media phobia once and for all.   |
Pharmaceutical Executive
February 1, 2014
Longacre et al. |
Social Media: Have We Reached The Tipping Point? For pharma marketers, the good news is recent advances in social media monitoring make it possible to listen to or engage with patients on social media websites. This month FDA released its draft guidance on the use of "Interactive Promotional Media." |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
The Motley Fool
August 22, 2007
Brian Orelli |
Yes? No? Maybe So? Roche is still after Ventana. While longtime investors are happy that Roche pointed out Ventana's undervaluation to the rest of the world, current investors think Roche's offer is still too low. |
Chemistry World
February 26, 2014
Ned Stafford |
Roche disputes unethical East German trial claims Clinical trials in the 1980s, performed in former communist East Germany by global pharmaceutical giant Hoffmann-La Roche, adhered to international standards and did not violate East German laws, according to a report issued by the company after a six month internal investigation. |
Bio-IT World
December 15, 2003
Kevin Davies |
The Road to Personalized Medicine FDA guidance on the road to genomic medicine is a welcome first step in what promises to be a contentious debate on how to integrate pharmacogenomics into routine medical practice. |
The Motley Fool
November 27, 2006
Brian Lawler |
Roche Says Goodbye to PDL The larger pharmaceutical drops out of daclizumab development. Investors, take note. |
Information Today
November 6, 2008
Michael LoPresti |
Global Network Initiative Seeks to Curb Censorship, Enable Freedom of Expression Three of the biggest corporate names in the online technology sector unveil a joint initiative to promote freedom of expression and privacy on the internet. |
The Motley Fool
July 21, 2008
Brian Lawler |
Roche Wants to Buy Genentech -- Again In what could become one of the biggest biotech deals ever, Roche announces that it is offering to pay $43.7 billion for the remaining Genentech shares it doesn't already own. |
The Motley Fool
July 16, 2007
Brian Orelli |
Ventana Says No, We Can't Talk In many ways, Ventana is actually a perfect match for Roche. But for now, this hostile takeover bid is stalled. Investors, take note. |
Chemistry World
June 26, 2012
Sarah Houlton |
Roche rapped for side-effect reporting failure Roche has been rapped by the European Medicines Agency for failing to report a large number of potential drug side-effects. The UK's Medicines and Healthcare products Regulatory Agency identified deficiencies in the company's medicine safety reporting system. |
BusinessWeek
November 25, 2009
Arlene Weintraub |
Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance. |
The Motley Fool
January 31, 2008
Brian Lawler |
Don't Forget Roche Roche, the largest biopharma, by market capitalization, had a terrific 2007. Since it is not publicly listed on the major U.S. stock exchanges, the company never gets its fair share of attention. |
Chemistry World
March 25, 2010
Leila Sattary |
Science advice rules published The publication of the long-awaited principles for scientific advice in government has met with a frosty response, with some U. K. critics calling for researchers to boycott the guidelines. |
BusinessWeek
July 1, 2010
Doherty & Waters |
Post-Buyout, Genentech's DNA Is Dominant Bought out for $47 billion, the biotech pioneer has gained the upper hand |
Chemistry World
April 5, 2013
Phillip Broadwith |
Roche to release Tamiflu trial data Swiss pharma company Roche has finally agreed to give independent researchers access to data on all 74 clinical trials it ran on the antiviral influenza drug Tamiflu (oseltamivir). |
The Motley Fool
December 11, 2006
Brian Lawler |
Roche's Early Present to Halozyme Assuming it works, Enhanze may be a platform technology that could be applied across a wide range of injected products. Roche isn't exactly betting the farm on its success, though, with only $20 million of guaranteed up-front money. Investors, take note. |
The Motley Fool
August 31, 2010
Rich Duprey |
Why Did My Stock Just Die? These stocks just rolled over. Can they come back? |
BusinessWeek
October 1, 2007
Conrad Wilson |
A Dream Team Of Drugs And Diagnosis? If a deal is struck, a Roche-Ventana team could help launch a medical revolution. |
HBS Working Knowledge
March 21, 2005
Lauren Keller Johnson |
Tips for the CEO Candidate Think you're ready to step up to the top job? Get in line---there's plenty of competition. Here's advice for ascension from a top recruiter. |
Fast Company
January 2002
George Anders |
Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents... |
The Motley Fool
March 28, 2008
Brian Lawler |
Amgen and Roche Still Duking It Out Amgen threatens to sue Roche for damages. |
Chemistry World
October 29, 2014
Phillip Broadwith |
CHF3bn redevelopment for Roche's Basel site Swiss pharma major Roche plans to spend CHF3 billion ( 2 billion pounds) over the next 10 years on redeveloping its headquarters in Basel. |
Salon.com
August 2, 2001
Ivan Oransky |
Human guinea pigs When people put their bodies on the line in medical trials, can they be sure that scientists aren't cutting corners or preoccupied with stock prices? |
The Motley Fool
August 14, 2008
Brian Lawler |
Genentech Asks Roche to Pay Up In one of the more friendly spurnings of a buyout offer in recent months, Genentech calls Roche's $89-per-share buyout offer too low, and very nicely implies that Roche should up its bid. |
Bio-IT World
April 2006
Mark D. Uehling |
Debating Clinical Registries and Databases The pharmaceutical industry has been forced by medical journal editors and Congress to make public more data about clinical trials. Registries are here, most people are used to them, and they're not going away. But can the industry do registries and databases better? |
The Motley Fool
January 29, 2008
Brian Lawler |
Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected. |
The Motley Fool
April 5, 2004
Charly Travers |
A Biotech's Transition to Drugs A deal with Roche gives ArQule's drug program a leg up. ArQule has spent the last year transitioning from a services company into a drug developer. Last week's deal with Roche could signify that the transition is complete. |
The Motley Fool
March 19, 2008
Brian Lawler |
Roche to Amgen: We Surrender Roche gives in to a judge's recommendation that it pay a higher royalty to Amgen on sales of its anemia drug Mircera. |
Insurance & Technology
May 16, 2007
Peggy Bresnick Kendler |
Effective Vendor Management Enables Insurance Companies to Get the Most Out of Software, IT Services and Outsourcing Contracts Questions and answers about insurer/vendor relationships. |
The Motley Fool
May 18, 2011
Brian Orelli |
If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship. |
The Motley Fool
July 20, 2005
Stephen D. Simpson |
Two Ways to Play Roche Trying to track Roche is a pain, so investors might want to think about Genentech instead. |
The Motley Fool
February 29, 2008
Brian Lawler |
Amgen Playing Hardball There are new developments in the Amgen and Roche patent fight over their anemia drugs. |
The Motley Fool
January 17, 2008
Brian Lawler |
The Good Times Roll for Pharmasset Shares ride high after the company releases positive clinical trial data. |
The Motley Fool
October 29, 2007
Brian Lawler |
Amgen Revisited Third-quarter financials fail to impress, but there was good news, too from the biotech leader. |
